Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 12/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.68 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.68 |
| ▸ | TMPRSS4 | Q9NRS4 | 5/20 | 0.65 |
| ▸ | KCNMA1 | Q12791 | 5/20 | 0.64 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30771722 | 1.00 | P2RX1 (0.68) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL1704851 | 0.87 | TMPRSS4 (0.67) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL10223864 | 0.85 | P2RX1 (0.65) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL18341307 | 0.84 | P2RX1 (0.64) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL30771732 | 0.84 | P2RX1 (0.64) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL24460167 | 0.84 | P2RX1 (0.71) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL16147455 | 0.83 | KCNMA1 (0.71) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL31093979 | 0.83 | KCNMA1 (0.71) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL330391 | 0.81 | P2RX1 (0.66) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 | |
| SCHEMBL11932152 | 0.81 | P2RX1 (1.00) | P2RX1P2RX4P2RX7TMPRSS4KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION | 2024-01-04 | — | — | US | claimed |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | claimed |
| EP-3313388-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | Duke University (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210289-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION | 2024-01-04 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2022109148-A1 | SMALL MOLECULE INHIBITORS OF SARS-COV-2 INFECTIONS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FIRST WAVE BIO, INC. | 2021-12-30 | — | — | US | disclosed |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | DUKE UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | disclosed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| EP-3313388-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | Duke University (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2017040864-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Biopharma (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| WO-2016210289-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FH, CS, ECHS1 | P2RX1 910/4885P2RX4 694/4885P2RX7 285/4885 |
| US-20240002332-A1 | Small Molecule Inhibitors of SARS-CoV-2 Infections | ACE2, ACE, TMPRSS2 | P2RX1 2669/4885P2RX4 3287/4885P2RX7 2285/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | P2RX1 848/4885P2RX4 655/4885P2RX7 271/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | P2RX1 848/4885P2RX4 655/4885P2RX7 271/4885 |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | P2RX1 901/4885P2RX4 686/4885P2RX7 288/4885 |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | SFRP1, FZD7, WNT1 | P2RX1 3423/4885P2RX4 3784/4885P2RX7 2757/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | P2RX1 848/4885P2RX4 655/4885P2RX7 271/4885 |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | P2RX1 848/4885P2RX4 655/4885P2RX7 271/4885 |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | SFRP1, FZD7, WNT1 | P2RX1 3423/4885P2RX4 3784/4885P2RX7 2757/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | P2RX1 910/4885P2RX4 694/4885P2RX7 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.